A61K 2239/21
Transmembrane domain
A61K2239/21 (Transmembrane domain) appears on 60 US grants and 515 published applications in this corpus.
Search patents in A61K- Granted patents
- 60
- Published applications
- 515
- Assignees
- 281
- Inventors
- 1,516
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 1 | 2 |
| 2018 | 0 | 7 |
| 2019 | 2 | 3 |
| 2020 | 0 | 5 |
| 2021 | 2 | 5 |
| 2022 | 4 | 12 |
| 2023 | 5 | 47 |
| 2024 | 12 | 176 |
| 2025 | 15 | 166 |
| 2026 | 19 | 88 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Humanized CD19 antibody and use thereof15 Sep 2026US 12,735,482 B2Gracell Bioscience (Shanghai) Co., Ltd.
- Methods and compositions for chimeric antigen receptor targeting cancer cells1 Sep 2026US 12,721,892 B2The University of North Carolina at Chapel Hill
- Antigen-binding protein targeting CD70 and use thereof1 Sep 2026US 12,721,893 B2
- Lipid nanoparticles and methods of manufacture and use thereof8 Oct 2026US 2026/0306659 A1Ablynx N. V.
- Viral vectors for cell therapy1 Oct 2026US 2026/0294971 A1
- Switch receptors1 Oct 2026US 2026/0295042 A1Hoffmann-La Roche Inc.
- Car-t cell targeting cll1, preparation method therefor and use thereof1 Oct 2026US 2026/0297519 A1Carbiogene Therapeutics Co., Ltd.
- Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function24 Sep 2026US 2026/0284108 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
Most cited
By later US patents
- Use of the CD2 signaling domain in second-generation chimeric antigen receptors31US 9,783,591 B2The Trustees of the University of Pennsylvania · 2017
- LILRB1-based chimeric antigen receptor13US 11,254,726 B2A2 Biotherapeutics, Inc. · 2022
- Use of the CD2 signaling domain in second-generation chimeric antigen receptors6US 10,501,519 B2The Trustees of the University of Pennsylvania · 2019
- Methods and composition for gene delivery using an engineered viral particle4US 11,191,784 B2The Trustees of the University of Pennsylvania · 2021
- Humanized anti-MUC1* antibodies4US 11,746,159 B2Minerva Biotechnologies Corporation · 2023